These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26873871)

  • 21. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
    Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
    Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
    Viswanathan P; Chaudhuri A; Bhatia R; Al-Atrash F; Mohanty P; Dandona P
    Endocr Pract; 2007 Sep; 13(5):444-50. PubMed ID: 17872344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
    Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K
    Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
    Horowitz M; Aroda VR; Han J; Hardy E; Rayner CK
    Diabetes Obes Metab; 2017 May; 19(5):672-681. PubMed ID: 28058769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.
    Jaiswal M; Martin CL; Brown MB; Callaghan B; Albers JW; Feldman EL; Pop-Busui R
    J Diabetes Complications; 2015; 29(8):1287-94. PubMed ID: 26264399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exenatide versus glibenclamide in patients with diabetes.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
    Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
    Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Summaries for patients. Exenatide therapy for type 2 diabetes.
    Ann Intern Med; 2007 Apr; 146(7):I18. PubMed ID: 17404346
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.
    Abdul-Ghani MA; Puckett C; Triplitt C; Maggs D; Adams J; Cersosimo E; DeFronzo RA
    Diabetes Obes Metab; 2015 Mar; 17(3):268-75. PubMed ID: 25425451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
    Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
    Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychological and quality of life changes in patients using GLP-1 analogues.
    Grant P; Lipscomb D; Quin J
    J Diabetes Complications; 2011; 25(4):244-6. PubMed ID: 21601480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Type 2 diabetic patient with reduced beta-cell function. New substance class: incretin-mimetics].
    MMW Fortschr Med; 2005 Aug; 147(31-32):55. PubMed ID: 16128203
    [No Abstract]   [Full Text] [Related]  

  • 36. [Exenatide convinces in a six-month study: HbA1c sunk significantly].
    MMW Fortschr Med; 2009 May; 151(19):51. PubMed ID: 19827448
    [No Abstract]   [Full Text] [Related]  

  • 37. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
    Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
    Montilla S; Marchesini G; Sammarco A; Trotta MP; Siviero PD; Tomino C; Melchiorri D; Pani L;
    Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1346-53. PubMed ID: 25300980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.
    Su K; Lv C; Ji Z; Wang Y; Wang H; Bai Y; Liu Y
    Am J Ther; 2018; 25(6):e609-e616. PubMed ID: 26844723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.